Close Menu

NEW YORK – Biotechnology company Freenome and ADC Therapeutics, an oncology drug discovery and development company, announced today that they have signed a biomarker development agreement.

The companies will use Freenome's multiomics platform for early cancer detection to identify patients who are most likely to respond to treatment with ADC's antibody drug conjugate loncastuximab tesirine (ADCT-402). ADC is currently evaluating ADCT-402 in a pivotal Phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.

Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.

Researchers examine changes in the genomes of emmer wheat populations where the climate has warmed, the BBC reports.

In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.